PTC Therapeutics announce the launch of Emflaza for the treatment of Duchenne muscular dystrophy (DMD) within the coming weeks, with an expected net price of $35,000.
News
-
Read more »
-
Read more »
What are the results from the clinical studies that led to the approval of edaravone, and how can patients access it in their country?
-
May 07, 2017Read more »
For the first time in 22 years, the US Food and Drug Administration (FDA) has approved a drug to treat patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease; a motor neuron disease characterised by muscular atrophy and weakness.
-
April 24, 2017Read more »
The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment
-
March 29, 2017Read more »
The PBS, Australia’s national program responsible for providing subsidised prescriptions, has announced the addition of several new medicines
-
April 26, 2016Read more »
Promising Results from Multiple Studies
-
March 18, 2016Read more »
The FDA approval of a promising new drug is offering new hope to multiple myeloma patients who have already been through various treatments.
-
February 09, 2016Read more »
A new treatment that targets a specific type of lung cancer has received FDA approval.
-
December 08, 2015Read more »
On Sunday former US president and Nobel Peace Prize laureate proclaimed to a Sunday school class that he is cancer-free.
-
Read more »
The Pharmaceutical and Medical Device Agency (PMDA), has granted marketing approval for the use of Edaravone for the treatment of ALS in Japan.
-
Read more »
Impressive results have been published last week regarding two new immunotherapies.
